Literature DB >> 11296696

Peroxisomal beta-oxidation and steatohepatitis.

M S Rao1, J K Reddy.   

Abstract

Fatty acid beta-oxidation occurs in both mitochondria and peroxisomes. Mitochondria catalyze the beta-oxidation of the bulk of short-, medium-, and long-chain fatty acids derived from diet, and this pathway constitutes the major process by which fatty acids are oxidized to generate energy. Peroxisomes are involved, preferentially, in the beta-oxidation chain shortening of very long chain fatty acids (VLCFAs) and in the process produce H2O2. Long-chain fatty acids and VLCFAs are also metabolized by the cytochrome P450 CYP4A omega-oxidation system to toxic dicarboxylic acids (DCAs) that serve as substrates for peroxisomal beta-oxidation, and this process also leads to the production of superoxide and H2O2. The genes encoding peroxisomal, microsomal, and certain mitochondrial fatty acid metabolizing enzymes in liver are transcriptionally regulated by peroxisome proliferator-activated receptor alpha (PPAR alpha). Deficiencies of the enzymes of peroxisomal beta-oxidation have been recognized as important causes of disease. Evidence from mice deficient in PPAR alpha (PPAR alpha-/-), deficient in peroxisomal fatty acyl-CoA oxidase (AOX-/-), the first enzyme of the classical beta-oxidation system, and deficient in both PPAR alpha and AOX (PPAR alpha-/-AOX-/-) points to the critical importance of PPAR alpha-inducible peroxisomal and microsomal oxidation systems that metabolize LCFAs and VLCFAs in the pathogenesis of nonalcoholic microvesicular hepatic steatosis and steatohepatitis. These and other mouse models should provide greater understanding of the molecular mechanism responsible for hepatic steatosis and steatohepatitis. Deficiency of AOX disrupts the oxidation of VLCFAs, DCAs, and other substrates leading to extensive microvesicular steatosis and steatohepatitis. Loss of this enzyme also causes sustained hyperactivation of PPAR alpha, leading to transcriptional up-regulation of PPAR alpha-regulated genes, indicating that unmetabolized substrates of AOX function as ligands of PPAR alpha. beta-Oxidation is the major process by which fatty acids are oxidized to generate energy, especially when glucose availability is low during periods of starvation. Mice deficient in PPAR alpha and those nullizygous for both PPAR alpha and AOX show a minimal steatotic phenotype under fed conditions but manifest an exaggerated steatotic response to fasting, indicating that defects in PPAR alpha-inducible fatty acid oxidation determine the severity of fatty liver phenotype to conditions reflecting energy-related stress.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11296696     DOI: 10.1055/s-2001-12928

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  48 in total

1.  Sonographic fatty liver and hepatitis B virus carrier status: synergistic effect on liver damage in Taiwanese adults.

Authors:  Yu-Cheng Lin; Shu-Tin Hsiao; Jong-Dar Chen
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

2.  Mice with a deletion in the gene for CCAAT/enhancer-binding protein beta are protected against diet-induced obesity.

Authors:  Carrie A Millward; Jason D Heaney; David S Sinasac; Eric C Chu; Ilya R Bederman; Danielle A Gilge; Stephen F Previs; Colleen M Croniger
Journal:  Diabetes       Date:  2007-01       Impact factor: 9.461

3.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

Review 4.  Inflammatory mediators of hepatic steatosis.

Authors:  Elizabeth Hijona; Lander Hijona; Juan I Arenas; Luis Bujanda
Journal:  Mediators Inflamm       Date:  2010-03-16       Impact factor: 4.711

5.  Dietary saponins of sea cucumber alleviate orotic acid-induced fatty liver in rats via PPARalpha and SREBP-1c signaling.

Authors:  Xiao-Qian Hu; Yu-Ming Wang; Jing-Feng Wang; Yong Xue; Zhao-Jie Li; Koji Nagao; Teruyoshi Yanagita; Chang-Hu Xue
Journal:  Lipids Health Dis       Date:  2010-03-09       Impact factor: 3.876

Review 6.  S-adenosylmethionine in liver health, injury, and cancer.

Authors:  Shelly C Lu; José M Mato
Journal:  Physiol Rev       Date:  2012-10       Impact factor: 37.312

Review 7.  Effects of resveratrol and other polyphenols in hepatic steatosis.

Authors:  Leixuri Aguirre; Maria Puy Portillo; Elizabeth Hijona; Luis Bujanda
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

8.  Peroxisome proliferator activated receptor-gamma in pathogenesis of experimental fatty liver disease.

Authors:  Cai-Yan Zhao; Ling-Ling Jiang; Li Li; Zhuo-Jun Deng; Bao-Li Liang; Jian-Mei Li
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

Review 9.  Molecular mechanisms involved in NAFLD progression.

Authors:  Mariano Malaguarnera; Michelino Di Rosa; Ferdinando Nicoletti; Lucia Malaguarnera
Journal:  J Mol Med (Berl)       Date:  2009-04-08       Impact factor: 4.599

Review 10.  A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease.

Authors:  P Riley; J O'Donohue; M Crook
Journal:  J Clin Pathol       Date:  2007-05-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.